Results 51 to 60 of about 72,883 (309)

Real-World Treatment Patterns among Patients with Alopecia Areata in the USA: A Retrospective Claims Analysis

open access: yesActa Dermato-Venereologica, 2023
Alopecia areata is an autoimmune disorder characterized by hair loss, for which there are few treatment options. This claims-based study characterized recent real-world treatment patterns among patients in the USA with alopecia areata, including the ...
Nicolae Done   +6 more
doaj   +1 more source

The epidemiology of alopecia areata: a population‐based cohort study in UK primary care

open access: yesBritish Journal of Dermatology, 2021
There is a lack of population‐based information on the disease burden and management of alopecia areata (AA).
M. Harries   +8 more
semanticscholar   +1 more source

Successful treatment of concomitant alopecia universalis and Crohn’s disease with upadacitinib: A case report

open access: yesSAGE Open Medical Case Reports, 2023
Alopecia areata is a non-scarring, autoimmune hair loss disorder that is associated with inflammatory bowel disease. Alopecia areata and inflammatory bowel disease may have a common pathogenic mechanism that involves the Janus kinase/STAT pathway.
Leah A Johnston   +2 more
doaj   +1 more source

Common Dermatoses in Patients with Obsessive Compulsive Disorders [PDF]

open access: yes, 2015
Obsessive-compulsive disorder is a chronic, debilitating syndrome, consisting of intrusive thoughts- which are experienced as inappropriate by the patient and are producing anxiety- and compulsions, defined as repetitive behaviours produced to reduce ...
Benea, Vasile   +4 more
core   +3 more sources

A Comprehensive Literature Review of JAK Inhibitors in Treatment of Alopecia Areata

open access: yesClinical, Cosmetic and Investigational Dermatology, 2021
Alopecia areata (AA) is a chronic, immune-mediated form of nonscarring alopecia that is multifactorial and results in localized patches. It is often described as a self-limiting condition that results in the spontaneous regrowth of hair in most cases ...
Kerry A. Dillon
semanticscholar   +1 more source

The Efficacy of Azelaic Acid 20% Cream in the Treatment of Scalp Alopecia Areata [PDF]

open access: yesالمجلة العراقية للصيدلة, 2022
Introduction: Alopecia areata is a common, inflammatory, non-scarring type of hair loss that affects persons of both sexes and all age groups, with prevalence in the general population of approximately 0.1–0.2%.
Mudheher Salih, Dindar Qurtas
doaj   +1 more source

Pili Annulati Coincident with Alopecia Areata, Autoimmune Thyroid Disease, and Primary IgA Deficiency: Case report and Considerations on the Literature [PDF]

open access: yes, 2007
Pili annulati is a rare autosomal dominant hair disorder clinically characterized by a pattern of alternating bright and dark bands of the hair, the bright bands appearing dark if observed by transmitted light.
Caputo, V., Castelli, E., Fiorella, S.
core   +3 more sources

Alopecia Areata: An Autoimmune Disease of Multiple Players

open access: yesImmunoTargets and Therapy, 2021
Alopecia areata (AA) is an autoimmune disease of the hair follicles. It is characterized by a well-defined non-scarring alopecic patch or patches that may extend to the entire scalp or lead to total body hair loss.
Poonkiat Suchonwanit   +2 more
semanticscholar   +1 more source

Alopecia Areata is Associated with Increased Expression of Heart Disease Biomarker Cardiac Troponin I

open access: yesActa Dermato-Venereologica, 2018
The development of androgenetic alopecia is associated with a risk of developing cardiovascular diseases, but the association of alopecia areata with cardiovascular diseases in humans is largely unexplored.
Eddy Hsi Wang   +7 more
doaj   +1 more source

Effectiveness and Predictive Factors of Response to Tofacitinib Therapy in 125 Patients with Alopecia Areata: A Single-centre Real-world Retrospective Study

open access: yesActa Dermato-Venereologica, 2023
Alopecia areata is an autoimmune disorder that greatly impacts patients’ quality of life, and its management remains challenging. Tofacitinib is the first Janus kinase inhibitor to be approved for clinical use and is the most extensively studied. Several
Jundong Huang   +5 more
doaj   +1 more source

Home - About - Disclaimer - Privacy